CN108697785B - Zika病毒疫苗 - Google Patents

Zika病毒疫苗 Download PDF

Info

Publication number
CN108697785B
CN108697785B CN201680074939.XA CN201680074939A CN108697785B CN 108697785 B CN108697785 B CN 108697785B CN 201680074939 A CN201680074939 A CN 201680074939A CN 108697785 B CN108697785 B CN 108697785B
Authority
CN
China
Prior art keywords
virus
zika virus
vaccine
zika
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680074939.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108697785A (zh
Inventor
J·巴尔贝罗卡尔扎多
M·内本菲尔
R·施勒格
M·韦伯
J·费鲁施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Valneva Austria GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108697785(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria GmbH filed Critical Valneva Austria GmbH
Priority to CN202210678575.3A priority Critical patent/CN115381934A/zh
Publication of CN108697785A publication Critical patent/CN108697785A/zh
Application granted granted Critical
Publication of CN108697785B publication Critical patent/CN108697785B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680074939.XA 2015-12-23 2016-12-23 Zika病毒疫苗 Active CN108697785B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210678575.3A CN115381934A (zh) 2015-12-23 2016-12-23 Zika病毒疫苗

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP15202585.4 2015-12-23
EP16161068.8 2016-03-18
EP16161068 2016-03-18
EP16176049.1 2016-06-23
EP16176025 2016-06-23
EP16176025.1 2016-06-23
EP16176049 2016-06-23
EP16182845.4 2016-08-04
EP16182845 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210678575.3A Division CN115381934A (zh) 2015-12-23 2016-12-23 Zika病毒疫苗

Publications (2)

Publication Number Publication Date
CN108697785A CN108697785A (zh) 2018-10-23
CN108697785B true CN108697785B (zh) 2022-08-02

Family

ID=57821924

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680074939.XA Active CN108697785B (zh) 2015-12-23 2016-12-23 Zika病毒疫苗
CN202210678575.3A Pending CN115381934A (zh) 2015-12-23 2016-12-23 Zika病毒疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210678575.3A Pending CN115381934A (zh) 2015-12-23 2016-12-23 Zika病毒疫苗

Country Status (19)

Country Link
US (14) US10744194B2 (enExample)
EP (9) EP3393507B1 (enExample)
JP (1) JP6949027B2 (enExample)
KR (1) KR20180097558A (enExample)
CN (2) CN108697785B (enExample)
AU (1) AU2016375338B2 (enExample)
BR (1) BR112018012873A2 (enExample)
CA (1) CA3009278A1 (enExample)
DK (1) DK3393510T5 (enExample)
ES (4) ES2973267T3 (enExample)
FI (1) FI3393510T3 (enExample)
HR (1) HRP20230273T1 (enExample)
HU (1) HUE061679T2 (enExample)
LT (1) LT3393510T (enExample)
MX (1) MX2018007627A (enExample)
PL (1) PL3393510T3 (enExample)
SG (1) SG11201805120YA (enExample)
SI (1) SI3393510T1 (enExample)
WO (6) WO2017109228A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
MY187459A (en) * 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
HUE061679T2 (hu) 2015-12-23 2023-08-28 Valneva Austria Gmbh Zika vírus vakcina
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
CR20200082A (es) 2017-09-21 2020-05-17 Valneva Se Virus chikungunya inmunogénico
US11648304B2 (en) * 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
KR20200090893A (ko) * 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN112088013B (zh) * 2018-03-26 2024-12-06 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
CN114206103A (zh) * 2019-01-22 2022-03-18 蓝鸟生物公司 用于制造病毒载体的方法和系统
CN113939311A (zh) * 2019-05-08 2022-01-14 武田疫苗股份有限公司 灭活病毒组合物和寨卡疫苗制剂
EP4010016A1 (en) 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine
BR112022002082A2 (pt) 2019-08-09 2022-04-12 Valneva Se Formulações de vacina contra o chikungunya
EP4028511A1 (en) 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
EP4114463A4 (en) 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
US20240189412A1 (en) * 2020-03-03 2024-06-13 Mayo Foundation For Medical Education And Research Zika Virus Polypeptides
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
EP4153222A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4476329A1 (en) * 2022-02-09 2024-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
CA2341354C (en) * 1998-09-02 2009-10-20 The Government Of The United States Of America Dengue viruses that are replication defective in mosquitos for use as vaccines
AU2009240738A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US8765148B2 (en) * 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
NZ503522A (en) * 1997-08-28 2001-06-29 Us Army Attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
DK3785730T3 (da) 2011-12-06 2024-05-06 Valneva Austria Gmbh Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
MY187459A (en) 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
HUE061679T2 (hu) 2015-12-23 2023-08-28 Valneva Austria Gmbh Zika vírus vakcina
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
CR20200082A (es) 2017-09-21 2020-05-17 Valneva Se Virus chikungunya inmunogénico

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341354C (en) * 1998-09-02 2009-10-20 The Government Of The United States Of America Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
AU2009240738A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US8765148B2 (en) * 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A purified inactivated Japanese encephalitis virus vaccine made in vero cells";Ashok K. Srivastava等;《Vaccine》;20010831;第19卷(第31期);第4457页摘要，第4459页左栏第3段-4560页左栏第2段，第4564页左栏第2段 *
"Predicting Zika virus structural biology: Challenges and opportunities for intervention";Bryan D Cox等;《Antiviral Chemistry & Chemotherapy》;20150831;第24卷(第3-4期);第118页摘要，第119页左栏第2-3段 *

Also Published As

Publication number Publication date
KR20180097558A (ko) 2018-08-31
JP2019504030A (ja) 2019-02-14
US20200017555A9 (en) 2020-01-16
WO2017109228A1 (en) 2017-06-29
EP4393938A2 (en) 2024-07-03
EP4357355A3 (en) 2024-09-25
EP4357355A2 (en) 2024-04-24
EP3393507C0 (en) 2024-02-07
EP3393507A1 (en) 2018-10-31
EP4253403A2 (en) 2023-10-04
US10660950B2 (en) 2020-05-26
JP6949027B2 (ja) 2021-10-20
SG11201805120YA (en) 2018-07-30
AU2016375338A1 (en) 2018-07-05
US20210093707A1 (en) 2021-04-01
WO2017109223A1 (en) 2017-06-29
US11331382B2 (en) 2022-05-17
ES2976311T3 (es) 2024-07-29
CA3009278A1 (en) 2017-06-29
US12005111B2 (en) 2024-06-11
US10537630B2 (en) 2020-01-21
EP4218807A3 (en) 2023-09-06
LT3393510T (lt) 2023-03-27
EP3393508B9 (en) 2023-09-27
ES2950887T3 (es) 2023-10-16
WO2017109227A1 (en) 2017-06-29
EP3393508C0 (en) 2023-06-07
CN108697785A (zh) 2018-10-23
WO2017109224A1 (en) 2017-06-29
US20180362936A1 (en) 2018-12-20
WO2017109225A1 (en) 2017-06-29
FI3393510T3 (fi) 2023-03-22
US12214033B2 (en) 2025-02-04
US11524064B2 (en) 2022-12-13
US20180369359A1 (en) 2018-12-27
EP3393506B1 (en) 2024-03-13
EP3393508B1 (en) 2023-06-07
AU2016375338B2 (en) 2021-11-04
US20240108712A1 (en) 2024-04-04
ES2973267T3 (es) 2024-06-19
US20200368342A1 (en) 2020-11-26
EP4218807A2 (en) 2023-08-02
US11951163B2 (en) 2024-04-09
US20190008945A1 (en) 2019-01-10
EP3393507B1 (en) 2024-02-07
EP4253403A3 (en) 2023-12-27
WO2017109229A1 (en) 2017-06-29
EP3393508A1 (en) 2018-10-31
US11219681B2 (en) 2022-01-11
US20250018023A1 (en) 2025-01-16
EP3393506C0 (en) 2024-03-13
HUE061679T2 (hu) 2023-08-28
CN115381934A (zh) 2022-11-25
PL3393510T3 (pl) 2023-06-26
MX2018007627A (es) 2019-02-14
US20230056142A1 (en) 2023-02-23
US11207397B2 (en) 2021-12-28
US20180371027A1 (en) 2018-12-27
HRP20230273T1 (hr) 2023-04-28
US10639365B2 (en) 2020-05-05
US20200384099A1 (en) 2020-12-10
EP3393509A1 (en) 2018-10-31
US20200197506A1 (en) 2020-06-25
US20180362937A1 (en) 2018-12-20
ES2941967T3 (es) 2023-05-29
US10744194B2 (en) 2020-08-18
DK3393510T5 (da) 2024-09-30
EP3393509B1 (en) 2024-02-28
US20230226165A1 (en) 2023-07-20
SI3393510T1 (sl) 2023-04-28
DK3393510T3 (da) 2023-03-13
EP4393938A3 (en) 2024-08-07
US12102673B2 (en) 2024-10-01
BR112018012873A2 (pt) 2018-12-04
EP3393509C0 (en) 2024-02-28
US11406700B2 (en) 2022-08-09
EP3393506A1 (en) 2018-10-31
EP3393510A1 (en) 2018-10-31
EP3393510B1 (en) 2023-02-22
US20220273786A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN108697785B (zh) Zika病毒疫苗
CN112626090B (zh) 一种编码新型冠状病毒抗原的核苷酸序列及其应用
JP2693145B2 (ja) 乳頭腫ウイルス型特異的抗体
JP4444372B2 (ja) 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント
KR20170102905A (ko) 신규 다가 나노입자 기반 백신
US6572862B1 (en) Methods and reagents to detect and characterize Norwalk and related viruses
CN112575008A (zh) 编码新型冠状病毒的结构蛋白的核酸分子以及新型冠状病毒疫苗
CN118271460A (zh) 痘病毒多抗原嵌合疫苗及其用途
CN118725053B (zh) 呼吸道合胞病毒融合前f蛋白突变体及其应用
US4810492A (en) Flavivirus antigen
WO1993021325A1 (en) Wild-type measles virus glycoproteins: vaccine and detection method therefor
CN115666633A (zh) CpG-佐剂的SARS-CoV-2病毒疫苗
HK40077936A (en) Zika virus vaccine
KR20210139315A (ko) 뎅기 바이러스 백신
HK1261387A1 (en) Zika virus vaccine
HK1261387B (en) Zika virus vaccine
US5486473A (en) A DNA coding for a Flavivirus antigen
RU2813150C2 (ru) Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа
AU2019310347A1 (en) Zika virus vaccine
WO2012030778A1 (en) Canine kobuvirus sequences and uses thereof
JP2025504887A (ja) コロナウイルス抗原バリアント
CN115768469A (zh) 灭活的SARS-CoV-2病毒疫苗
CN117903260A (zh) Ppv多肽抗原和组合物及其应用、ppv疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261387

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant